Regulatory and reimbursement innovation

Science Translational Medicine

Volumn 5, Issue 176, 2013, Pages

  Lindor, Rachel A ^a,b   Allocco, Scott J ^c   Cheatham, Lee ^a   Cortese, Denis A ^a   Hall, Ralph F ^d   Mangold, William J ^e   Pizziconi, Vincent ^f   Poste, George ^a   Quinn, Bruce ^g   Roth, Mollie ^h   Saks, Michael J ⁱ   Wassman, E Robert ⁱ   Woosley, Raymond L ^j   Marchant, Gary E ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c SJA Healthcare Strategies   (United States)

^d UNIVERSITY OF MINNESOTA LAW SCHOOL   (United States)

^e Medicare Contractor Medical   (United States)

^f Arizona State University   (United States)

^g Foley Hoag LLP   (United States)

^h Diaceutics   (United Kingdom)

ⁱ Generation Health/CVS (Now MetaDiagnostic)   (United States)

^j AZCERT Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH PROGRAM; INTEGRATION; MEDICARE; MOLECULAR DIAGNOSTICS; ORGANIZATION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROGNOSIS; REIMBURSEMENT; REVIEW;

EID: 84875176518     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3005437     Document Type: Review

References (10)

1. S. S. Dhruva, S. E. Phurrough, M. E. Salive, R. F. Redberg, CMS's landmark decision on CT colonography-Examining the relevant data. N. Engl. J. Med. 360, 2699-2701 (2009).
2. U.S. White House, National Bioeconomy Blueprint (April 2012); www.whitehouse.gov/sites/default/fi les/microsites/ostp/national-bioeconomy- blueprint-april-2012.pdf.
3. Genome-Based Diagnostics: Clarifying Pathways to Clinical Use-Workshop Summary (Institute of Medicine, Washington, DC., 2012); www.iom.edu/Reports/ 2012/Genome-Based-Diagnostics-Clarifying-Pathways-to- Clinical-Use.aspx.
4. R. A. Lindor, Advancing evidence-based medicine by expanding coverage with evidence development. Jurimetrics 52, 209-237 (2012).
5. M. R. Gillick, Medicare coverage for technological innovations- Time for new criteria? N. Engl. J. Med. 350, 2199-2203 (2004). (Pubitemid 38659502)
6. S. R. Tunis, S. D. Pearson, Coverage options for promising technologies: Medicare's 'coverage with evidence development'. Health Af . 25, 1218-1230 (2006). (Pubitemid 44497620)
7. CMS, CED Public Solicitation (7 November 2011): www.cms.gov/medicare- coverage-database/details/medicare-coverage-document-details.aspx?MCDId= 8&McdName=CED+Public+Solicitation&mcdtypename=Guidance+Documents& MCDIndexType=1&c=AgAEAAAAAAAA&.
8. CMS, National Coverage Determination (NCD) for pharmacogenomic testing for warfarin response (90.1) (5 April 2010); www.cms.gov/Medicare/Medicare- Contracting/ContractorLearningResources/downloads/JA6715.pdf.
9. CMS and FDA, Pilot program for parallel review of medical products, 76 Fed. Reg. 62808-62810 (11 October 2011).
10. D. A. Messner, S. R. Tunis, Current and future state of FDA-CMS parallel reviews. Clin. Pharm. Therapeut. 91, 383-385 (2012).